Premium
Effects of methylphenidate on quality of life in children with both developmental coordination disorder and ADHD
Author(s) -
Flapper Boudien CT,
Schoemaker Marina M
Publication year - 2008
Publication title -
developmental medicine and child neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.658
H-Index - 143
eISSN - 1469-8749
pISSN - 0012-1622
DOI - 10.1111/j.1469-8749.2008.02039.x
Subject(s) - methylphenidate , quality of life (healthcare) , attention deficit hyperactivity disorder , placebo , psychology , proxy (statistics) , cognition , health related quality of life , medicine , clinical psychology , pediatrics , psychiatry , alternative medicine , disease , pathology , psychotherapist , machine learning , computer science
Measurement of health‐related quality of life (HRQOL) in attention‐deficit‐hyperactivity disorder (ADHD) gives a more complete picture of day‐to‐day functioning and treatment effects than behavioural rating alone. The aim of this pilot study was to investigate the impact of the combined diagnoses of developmental coordination disorder (DCD) and ADHD on HRQOL, and the effectiveness of methylphenidate (MPH) on HRQOL. HRQOL was established using the Dutch‐Child‐AZL‐TNO‐Quality‐of‐Life (DUX‐25) and the TNO‐AZL‐Child‐Quality‐of‐Life (TACQOL) questionnaires, completed by children and parents. HRQOL of these children was compared with that of 23 age‐ and sex‐matched healthy controls. Twenty‐three children (21 males, two females; mean age 8y 6mo, [SD 3mo] range 7y‐10y 8mo) with ADHD/DCD entered a 4‐week, open‐label MPH study, after MPH‐sensitivity was established, in a double‐blind, placebo‐controlled trial. In these children's self‐ and proxy reports, impact of both DCD and ADHD was reflected in lower general well‐being (self and proxy report p=0.001) due to lower functioning in motor (selfp=0.026; proxy 0.001), autonomic (self p <0.001; proxy p =0.047), cognitive (self p =0.001; proxy p =0.01), and social (self and proxy p <0.001) domains. HRQOL scores improved in 18 children receiving MPH ( p =0.001) versus controls. The ADHD /DCD group also demonstrated a significant improvement in ADHD symptoms ( p <0.001) and motor functioning ( p <0.001). Additional motor therapy will still be needed in about half of the children with ADHD/DCD receiving MPH, within multimodal treatment including educational and psychosocial assistance.